Belite Bio (NASDAQ:BLTE) Shares Down 7.4% – Time to Sell?

Shares of Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) were down 7.4% on Friday. The company traded as low as $157.65 and last traded at $157.3360. Approximately 35,932 shares were traded during mid-day trading, a decline of 81% from the average daily volume of 190,025 shares. The stock had previously closed at $169.96.

Key Belite Bio News

Investors following BLTE have been watching these news items:

• Positive Sentiment: The FDA accepted Belite Bio’s NDA for tinlarebant for priority review, advancing the company’s effort to bring a treatment for Stargardt disease to market. Priority review may shorten the review timeline, though approval is not guaranteed. Belite Bio Q3 2026 earnings call highlights
• Positive Sentiment: Belite reported a third-quarter loss of $0.60 per share, narrower than analysts’ expected loss of $0.79, providing a modest earnings beat. Belite Bio quarterly earnings results
• Positive Sentiment: Shares were reported to have moved above their 200-day moving average, a technical signal that some investors may view as improving momentum. Belite Bio share price breaks above 200-day moving average

Wall Street Analyst Weigh In

A number of analysts have recently commented on BLTE shares. Weiss Ratings restated a “sell (d-)” rating on shares of Belite Bio in a research note on Friday, October 2nd. Morgan Stanley raised their price target on shares of Belite Bio from $201.00 to $206.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Benchmark restated a “buy” rating on shares of Belite Bio in a research report on Friday, August 14th. Cantor Fitzgerald lifted their price target on Belite Bio from $266.00 to $270.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 12th. Finally, Zacks Research cut Belite Bio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 18th. Eight research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $227.40.

Belite Bio Price Performance

The stock’s fifty day moving average is $161.02 and its 200-day moving average is $160.25. The stock has a market cap of $6.50 billion, a PE ratio of -59.14 and a beta of -1.19.

Belite Bio (NASDAQ:BLTE) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.19. On average, sell-side analysts expect that Belite Bio, Inc. Sponsored ADR will post -3.08 EPS for the current fiscal year.

Insider Activity

In other news, CFO Hao-Yuan Chuang sold 17,962 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $196.42, for a total transaction of $3,528,096.04. Following the completion of the sale, the chief financial officer owned 26,038 shares in the company, valued at $5,114,383.96. This trade represents a 40.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Hendrik Scholl sold 500 shares of Belite Bio stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $165.32, for a total transaction of $82,660.00. Following the sale, the insider directly owned 14,500 shares in the company, valued at approximately $2,397,140. The trade was a 3.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 168,330 shares of company stock valued at $31,969,118 in the last 90 days. Company insiders own 13.29% of the company’s stock.

Institutional Investors Weigh In On Belite Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Affinity Asset Advisors LLC raised its position in Belite Bio by 225.0% in the first quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company’s stock valued at $10,364,000 after purchasing an additional 45,000 shares during the period. Candriam S.C.A. purchased a new position in shares of Belite Bio during the 3rd quarter worth $10,711,000. The Manufacturers Life Insurance Company purchased a new position in shares of Belite Bio during the 1st quarter worth $3,125,000. Renaissance Technologies LLC acquired a new stake in shares of Belite Bio during the 1st quarter worth about $8,291,000. Finally, Amundi acquired a new stake in shares of Belite Bio during the 1st quarter worth about $671,000. Institutional investors and hedge funds own 0.53% of the company’s stock.

Belite Bio Company Profile

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.